Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases

被引:34
作者
Mushtaq, Shazad [1 ]
Meunier, Daniele [1 ]
Vickers, Anna [1 ]
Woodford, Neil [1 ]
Livermore, David M. [1 ,2 ]
机构
[1] Publ Hlth England, Antimicrobial Resistance & Healthcare Associated, 61 Colindale Ave, London NW9 5EQ, England
[2] Univ East Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England
关键词
RESISTANCE; HOSPITALS; POTENTIATION; WIDESPREAD; BACTEREMIA; MECHANISMS; IMIPENEM; KPC;
D O I
10.1093/jac/dkaa456
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: ESBL- and carbapenemase-producing Pseudomonas aeruginosa are prevalent in, for example, the Middle East, Eastern Europe and Latin America, though rarer elsewhere. Because P. aeruginosa readily mutate to become carbapenem resistant via Loss of OprD, isoLates producing ESBLs are often as broadly resistant as those producing carbapenemases. We hypothesized that: (i) reLebactam might overcome doss A carbapenemases directly in P. aeruginosa; and (ii) reLebactam's inhibition of AmpC, which gives a generalized potentiation of imipenem against the species, might restore imipenem susceptibility in OprD-deficient ESBL producers. Methods: MICs were determined using CLSI agar dilution for P. aeruginosa isolates producing ESBLs, principally VEB types, and for those producing GES-5, KPC and other carbapenemases. Results: Relebactam potentiated imipenem by around 4-8-fold for most P. aeruginosa isolates producing VEB and other ESBLs; however, MICs were typically onLy reduced to 4-16 mg/L, thus mostLy remaining above EUCAST's susceptibLe range and only party overlapping CLSI's intermediate range. Strong (approx. 64-fold) potentiation was seen for isolates producing KPC carbapenemases, but onLy 2-fold synergy for those with GES-5. Predictably, potentiation was not seen for isolates with doss B or D carbapenemase activity. Conclusions: Relebactam did potentiate imipenem against ESBL-producing P. aeruginosa, which are mostly imipenem resistant via OprD Loss, but this potentiation was generally insufficient to reduce imipenem MICs to the clinical range. Imipenem resistance owing to KPC carbapenemases was reversed by relebactam in P. aeruginosa, just as for Enterobacterales.
引用
收藏
页码:434 / 442
页数:9
相关论文
共 29 条
  • [1] Emergence of KPC-Producing Pseudomonas aeruginosa in Trinidad and Tobago
    Akpaka, Patrick E.
    Swanston, William H.
    Ihemere, Hyginus N.
    Correa, Adriana
    Torres, Julian A.
    Tafur, Jose D.
    Camila Montealegre, Maria
    Quinn, John P.
    Virginia Villegas, Maria
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (08) : 2670 - 2671
  • [2] Genotypes, carbapenemase carriage, integron diversity and oprD alterations among carbapenem-resistant Pseudomonas aeruginosa from Russia
    Bocharova, Yuliya
    Savinova, Tatiana
    Lazareva, Anna
    Polikarpova, Svetlana
    Gordinskaya, Nataliya
    Mayanskiy, Nikolay
    Chebotar, Igor
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (04)
  • [3] CLSI, 2015, CLSI Document M07-A10
  • [4] EUCAST, PREV VERS BREAKP DOC
  • [5] Widespread of ESBL- and carbapenemase GES-type genes on carbapenem-resistant Pseudomonas aeruginosa clinical isolates: a multicenter study in Mexican hospitals
    Garza-Ramos, Ulises
    Barrios, Humberto
    Reyna-Flores, Fernando
    Tamayo-Legorreta, Elsa
    Catalan-Najera, Juan C.
    Morfin-Otero, Rayo
    Rodriguez-Noriega, Eduardo
    Volkow, Patricia
    Cornejo-Juarez, Patricia
    Gonzalez, Alejandra
    Gaytan-Martinez, Jesus
    del Rocio Gonzalez-Martinez, Marisela
    Vazquez-Farias, Maria
    Silva-Sanchez, Jesus
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2015, 81 (02) : 135 - 137
  • [6] Pseudomonas aeruginosa sequence type 357 with VEB extended-spectrum β-lactamases in the UK: relatedness and resistance
    Greenwood, Beckie
    Meunier, Daniele
    Hopkins, Katie L.
    Pike, Rachel
    Ivanov, Zdravko
    Turton, Jane F.
    Hill, Robert
    Woodford, Neil
    Livermore, David M.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 52 (02) : 301 - 302
  • [7] Epidemiology and Characteristics of Metallo-beta-Lactamase-Producing Pseudomonas aeruginosa
    Hong, Duck Jin
    Bae, Il Kwon
    Jang, In-Ho
    Jeong, Seok Hoon
    Kang, Hyun-Kyung
    Lee, Kyungwon
    [J]. INFECTION AND CHEMOTHERAPY, 2015, 47 (02) : 81 - 97
  • [8] Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections
    Horner, Carolyne
    Mushtaq, Shazad
    Livermore, David M.
    Allen, M.
    Brown, D. F. J.
    Johnson, A. P.
    Longshaw, C.
    Livermore, D. M.
    MacGowan, A. P.
    Woodford, N.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (07) : 1940 - 1944
  • [9] Nosocomial spread of class 1 integron-carrying extensively drug-resistant Pseudomonas aeruginosa isolates in a Thai hospital
    Kiddee, Anong
    Henghiranyawong, Kritsada
    Yimsabai, Jutharak
    Tiloklurs, Mujarin
    Niumsup, Pannika R.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (04) : 301 - 306
  • [10] PER-1 is still widespread in Turkish hospitals among Pseudomonas aeruginosa and Acinetobacter spp.
    Kolayli, F
    Gacar, G
    Karadenizli, A
    Sanic, A
    Vahaboglu, H
    [J]. FEMS MICROBIOLOGY LETTERS, 2005, 249 (02) : 241 - 245